Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 10/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12830437 | 0.93 | KMT2A (0.58) | TAS1R3TAS1R1TAS1R2MEN1GAA | |
| SCHEMBL12756762 | 0.89 | NPC1 (0.46) | TAS1R3TAS1R1TAS1R2NAMPT | |
| SCHEMBL12756747 | 0.87 | HDAC2 (0.46) | TAS1R3TAS1R1TAS1R2HDAC2NAMPT | |
| SCHEMBL12830435 | 0.86 | HDAC2 (0.42) | TAS1R3TAS1R1TAS1R2MEN1GAA | |
| SCHEMBL12756750 | 0.82 | RAB9A (0.58) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1895278 | 0.80 | ANO1 (0.60) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL12756737 | 0.80 | NPY5R (0.48) | MEN1KMT2AHDAC2 | |
| SCHEMBL12756545 | 0.78 | ANO1 (0.49) | MEN1KMT2A | |
| SCHEMBL12756744 | 0.77 | P2RX7 (0.40) | MEN1KMT2A | |
| SCHEMBL12830909 | 0.76 | ANO1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TAS1R3 3820/4885TAS1R1 3836/4885TAS1R2 3547/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TAS1R3 3820/4885TAS1R1 3836/4885TAS1R2 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.